NasdaqCM - Nasdaq Real Time Price USD

PAVmed Inc. (PAVM)

0.7231

+0.0169

+(2.39%)

At close: May 13 at 4:00:01 PM EDT

0.7300

+0.01

+(0.95%)

After hours: May 13 at 5:36:46 PM EDT

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strate

PR Newswire 12 days ago

PAVM
+2.39%

PAVMZ

LUCD
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In a

PR Newswire 13 days ago

LUCD

PAVM
+2.39%

PAVMZ
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know

PAVmed (PAVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 15 days ago

PAVMZ
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced positive data from a National Cancer Institute (NCI)-sponsored study demonstrating that its EsoGuard® Esophageal DNA Test can effectively detect esophageal precancer (Barrett's Esophagus or BE) among at-risk patients without symptoms of chronic gastroesophageal reflux disease (GERD), such as heartburn. T

PR Newswire 19 days ago

PAVM
+2.39%

PAVMZ

LUCD
Lucid Diagnostics Announces Closing of Public Offering of Common Stock

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock, including 1,875,000 shares issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a public offering price of $1.20 per share.

PR Newswire last month

PAVM
+2.39%

PAVMZ

LUCD
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $1.20 per share. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less

PR Newswire last month

PAVM
+2.39%

PAVMZ

LUCD
Lucid Diagnostics Announces Proposed Public Offering of Common Stock

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its intention to offer shares of common stock through an underwritten public offering. The Company also plans to grant the underwriters a 45-day option to purchase additional shares of common stock. Proceeds from the offering are expected to support working capital and general corporate purposes. Complet

PR Newswire last month

LUCD

PAVM
+2.39%

PAVMZ
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 11:00 AM EDT.

PR Newswire last month

LUCD

PAVM
+2.39%

PAVMZ
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced a campaign, entitled "Embrace the Future", designed to showcase its groundbreaking EsoCheck® Esophageal Cell Collection Device, with Collect+Protect™ Technology, to gastroenterologists and the broader medical community. The campaign will coincide with Esophageal Cancer Awareness Month this April and will

PR Newswire last month

PAVM
+2.39%

PAVMZ

LUCD
PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Growth and Financial Stability

PAVmed Inc (PAVM) reports significant growth in test volumes and revenue, while securing strategic partnerships and funding to bolster future operations.

GuruFocus.com last month

PAVMZ

LUCD
Q4 2024 PAVmed Inc Earnings Call

Q4 2024 PAVmed Inc Earnings Call

Thomson Reuters StreetEvents last month

PAVMZ

LUCD
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the fourth quarter and full year ended December 31, 2024.

PR Newswire last month

PAVM
+2.39%

PAVMZ

LUCD
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2024.

PR Newswire last month

PAVM
+2.39%

PAVMZ

LUCD
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that a recent update to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) focused on Esophageal and Esophagogastric Junction Cancers (Version 1.2025) has added a new section on esophageal precancer (Barrett's Esophagus or BE) screening. The NCCN

PR Newswire last month

PAVM
+2.39%

PAVMZ

LUCD
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that its ENVET-BE clinical utility study has been accepted for publication in Gastroenterology & Hepatology—the fifth peer-reviewed publication of clinical utility data for Lucid's EsoGuard® Esophageal DNA Test, and the second to present findings from a real-world screening population. The manuscript, ent

PR Newswire last month

LUCD

PAVM
+2.39%

PAVMZ
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Highmark Blue Cross Blue Shield, an independent licensee of the Blue Cross and Blue Shield Association, has issued a positive coverage policy for non-invasive screening of esophageal precancer and cancer in New York state. The new policy will cover Lucid's EsoGuard® Esophageal DNA Test in patients wh

PR Newswire last month

PAVM
+2.39%

PAVMZ

LUCD
PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, March 25, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strat

PR Newswire 2 months ago

PAVM
+2.39%

PAVMZ
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Monday, March 24, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In ad

PR Newswire 2 months ago

PAVM
+2.39%

PAVMZ

LUCD
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced registered direct offering of 13,939,331 shares of common stock at a purchase price of $1.10 per share.

PR Newswire 2 months ago

LUCD

PAVM
+2.39%

PAVMZ
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into subscription agreements with certain accredited investors to sell 13,939,331 shares of common stock at a purchase price of $1.10 per share in a registered direct offering. The gross proceeds to the Company from this offering are expected to be approximately $15.3 million, before

PR Newswire 2 months ago

LUCD

PAVM
+2.39%

PAVMZ

Performance Overview

Return	PAVM	S&P 500 (^GSPC)
YTD	+15.14%	+0.08%
1-Year	-62.34%	+12.74%
3-Year	-95.32%	+46.29%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PAVmed Inc. (PAVM)

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Growth and Financial Stability

Q4 2024 PAVmed Inc Earnings Call

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

Performance Overview